Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems Inc. (NYSE: INSP) provides innovative neurostimulation solutions for obstructive sleep apnea (OSA) treatment. This news hub offers investors and healthcare professionals centralized access to official updates, including FDA milestones, clinical trial results, and strategic developments.
Track the company’s progress in advancing minimally invasive therapies through verified press releases, regulatory filings, and market expansion announcements. Key updates include earnings reports, partnership agreements, and advancements in OSA treatment technology.
Discover how Inspire Medical maintains compliance with global medical device standards while delivering clinically validated solutions. Content is organized chronologically for efficient research, with clear sourcing to ensure reliability.
Bookmark this page for real-time updates on INSP’s neurostimulation innovations and their impact on sleep medicine. For comprehensive analysis, combine these primary sources with third-party market commentary available across Stock Titan.
Inspire Medical Systems (NYSE: INSP) reported third quarter 2025 results on November 3, 2025, with Q3 revenue of $224.5M (up 10% YoY) and gross margin of 85.8%. The company reported net income of $9.9M and adjusted net income of $11.2M, with diluted EPS of $0.34 and adjusted diluted EPS of $0.38. Operating cash flow for Q3 was $68.5M. Management completed $50M of share repurchases and reported strong early adoption of the Inspire V system with positive clinical and procedural results. Inspire reaffirmed 2025 revenue guidance of $900M–$910M, maintained gross margin guidance of 84%–86%, and raised diluted net income per share guidance to $0.90–$1.00 from $0.40–$0.50.
Inspire Medical Systems (NYSE: INSP) announced that its management will present at the 2025 UBS Global Healthcare Conference on Monday, November 10, 2025 at 11:45 a.m. ET. The presentation will be available via live webcast and a replay will be posted for two weeks in the Event Archive on Inspire’s investor website at https://investors.inspiresleep.com. The session covers the company’s recent business developments and investor outreach at the UBS conference.
Inspire Medical Systems (NYSE: INSP) published clinical and limited-market data for the new Inspire V hypoglossal nerve stimulation system presented at ISSS/AAO-HNS (Oct 9–14, 2025).
Key results: Inspire V showed an IPOP of 87.1% vs 79.4% for Inspire IV, a reported 20% reduction in surgical time, strong adherence (Singapore mean 5.5±1.7 h/night at ~246 days; US limited release mean 6.8 h/night at 60 days) and median AHI reductions from 34.4 to 8.3 events/hour (Singapore, 37 patients at 6 months) and from 30 to 4.5 events/hour (US, first 34 patients).
Safety: no serious adverse events in the US cohort; two Singapore patients required short postoperative antibiotics. Additional patients remain to complete six-month follow-up for publication.
Inspire Medical Systems (NYSE: INSP) will report third quarter 2025 financial results after the close of trading on Monday, November 3, 2025. Management will host a conference call at 5:00 p.m. Eastern Time to discuss results and recent business developments.
A live webcast will be available on the company’s Investor Relations page and registrants who intend to ask questions must register to receive dial‑in details and a unique access code. The company recommends registering at least 10 minutes before the call. A replay will be posted on the Investor Relations site about two hours after the call and will be archived for two weeks.
Inspire Medical Systems (NYSE:INSP), a medical technology company specializing in sleep apnea solutions, announced that CFO Rick Buchholz will step down effective December 31, 2025. Buchholz will continue as a financial advisor through February 28, 2026 to ensure transition.
During Buchholz's tenure since 2014, the company achieved significant milestones, including revenue growth from $4 million to over $800 million in 2024, successful IPO completion, and reaching profitability. The company reaffirmed its 2025 guidance with revenue of $900-910 million, gross margin of 84-86%, and diluted EPS of $0.40-$0.50.
Inspire Medical Systems (NYSE:INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in the upcoming Wells Fargo 2025 Healthcare Conference.
The company's management team will deliver their presentation on Wednesday, September 3, 2025, at 11:00 a.m. Eastern Time. Investors can access the presentation through a live webcast, with a replay available for two weeks afterward on the company's investor website at investors.inspiresleep.com.
Inspire Medical Systems (NYSE:INSP), a medical technology company specializing in obstructive sleep apnea solutions, has announced a $200 million share repurchase program authorized by its Board of Directors. The program will run through August 7, 2027.
The announcement comes following the full U.S. launch of Inspire V, the company's next-generation neurostimulation system, representing their largest product launch to date. CEO Tim Herbert emphasized the company's strong financial position, which enables both capital return to shareholders and continued growth investments.
The company maintains flexibility in executing the buyback through various means, including open market purchases and private transactions, with no obligation for a specific number of shares.
Inspire Medical Systems (NYSE:INSP) reported mixed Q2 2025 financial results, with revenue growing 11% year-over-year to $217.1 million. The company posted a net loss of $3.6 million, or $0.12 per share, compared to net income of $9.8 million in Q2 2024. Adjusted net income was $13.3 million ($0.45 per share).
The company launched its next-generation Inspire V neurostimulation system in the U.S., though the rollout is progressing slower than anticipated. Due to these operational challenges, INSP revised its full-year 2025 guidance downward, now expecting revenue of $900-910 million (previously $940-955 million) and diluted EPS of $0.40-0.50 (down from $2.20-2.30).
Additionally, Randy Ban, Executive VP of Patient Access and Therapy Development, announced his retirement effective January 30, 2026.
Inspire Medical Systems (NYSE: INSP) has scheduled its second quarter 2025 financial results release for August 4, 2025 after market close. The company will host a conference call at 5:00 p.m. Eastern Time to discuss financial performance and business updates.
Investors can access the earnings call through two methods: a webcast via the company's Investor Relations website for those planning to listen only, or a separate registration link for those intending to ask questions. The company recommends registering at least 10 minutes before the call. A replay will be available on the Investor Relations website approximately two hours after the event and will be archived for two weeks.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
